Healthcare provider profile · identity verified

Beena Kumar, MD

Family Practice · BLOOMINGTON, MN · NPI 1629044698

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	391	104
Amlodipine Besylate	Amlodipine Besylate	321	82
Levothyroxine Sodium	Levothyroxine Sodium	174	42
Lisinopril	Lisinopril	173	50
Losartan Potassium	Losartan Potassium	155	43
Metoprolol Succinate	Metoprolol Succinate	148	38
Gabapentin	Gabapentin	141	38
Simvastatin	Simvastatin	125	31
Omeprazole	Omeprazole	114	31
Metformin Hcl	Metformin Hcl	108	28
Furosemide	Furosemide	106	30
Sertraline Hcl	Sertraline Hcl	106	25
Trazodone Hcl	Trazodone Hcl	84	30
Hydrochlorothiazide	Hydrochlorothiazide	83	23
Eliquis	Apixaban	76	16
Albuterol Sulfate Hfa	Albuterol Sulfate	74	28
Rosuvastatin Calcium	Rosuvastatin Calcium	72	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	71	19
Potassium Chloride	Potassium Chloride	65	18
Pravastatin Sodium	Pravastatin Sodium	65	17
Xarelto	Rivaroxaban	62	11
Tamsulosin Hcl	Tamsulosin Hcl	59	14
Fluticasone Propionate	Fluticasone Propionate	58	30
Warfarin Sodium	Warfarin Sodium	58	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	56	14
Jantoven	Warfarin Sodium	52	suppressed
Mirtazapine	Mirtazapine	48	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	46	12
Duloxetine Hcl	Duloxetine Hcl	41	suppressed
Bupropion Xl	Bupropion Hcl	38	suppressed
Glipizide Er	Glipizide	34	suppressed
Atenolol	Atenolol	32	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Carvedilol	Carvedilol	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Famotidine	Famotidine	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	14
Risperidone	Risperidone	28	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Ozempic	Semaglutide	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	25	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Allopurinol	Allopurinol	23	suppressed
Divalproex Sodium Er	Divalproex Sodium	22	suppressed
Jardiance	Empagliflozin	20	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Cyclosporine	Cyclosporine	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Tradjenta	Linagliptin	18	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Prednisone	Prednisone	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	12
Enoxaparin Sodium	Enoxaparin Sodium	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Gemtesa	Vibegron	13	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Torsemide	Torsemide	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Colestipol Hcl	Colestipol Hcl	12	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Nystatin	Nystatin	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error